Serum Omentin-1 Level as a Biomarker in Prostate Cancer

Authors

  • Ali Miqdad Mohammed Department of Biochemistry, College of Medicine, University of Basrah, Basrah, Iraq.
  • Abrar I. Albadr Department of Biochemistry, College of Medicine, University of Basrah, Basrah, Iraq.
  • Haider Jaber Sagban Medical Oncologist (Iraqi Board), President of Arab Board for Oncology in Iraq, Iraq.

DOI:

https://doi.org/10.31557/apjcb.2026.11.2.435-441

Keywords:

Diagnostic biomarkers, Omentin-1, Prostate cancer.

Abstract

Objective: To evaluate serum omentin-1 levels in prostate cancer patients relative to healthy controls and to assess its variation between tumor stages and Gleason score categories.

Methodology: This case-control research involved 176 participants (88 prostate cancer patients and 88 controls) from the National Teaching Oncology Hospital in Najaf, Iraq. Serum omentin-1 concentrations were verified by ELISA tests, and relationships with PSA, BMI were measured. ROC analysis was used to assess diagnostic efficacy.

Results: Omentin-1 levels were markedly elevated in prostate cancer patients (43.4 ± 22.6 ng/mL) compared to controls (26.1 ± 6.6 ng/mL, p < 0.01). ROC analysis showed reasonable diagnostic accuracy (AUC = 0.73).

Conclusion: Serum omentin-1 levels are elevated in prostate cancer, and no significant differences were observed across tumor stages or Gleason score categories, indicating that its elevation does not appear to be stage-dependent in this cohort. Further studies are needed to elucidate the mechanistic role of omentin-1 in prostate carcinogenesis, as well as its diagnostic and prognostic potential.

 

Downloads

Published

2026-04-29

How to Cite

1.
Mohammed AM, Albadr AI, Sagban HJ. Serum Omentin-1 Level as a Biomarker in Prostate Cancer. Asian Pac J Cancer Biol [Internet]. 2026 Apr. 29 [cited 2026 Jun. 19];11(2):435-41. Available from: https://www.waocp.com/journal/index.php/apjcb/article/view/2274

Issue

Vol. 11 No. 2 (2026)

Section

Research Articles/ Original Work

License

 West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).